Abaloparatide
Also known as: Tymlos, BA058
At a glance
PeptiGuide dataset · reviewed Aug 2026
What it is
An FDA-approved PTHrP analog studied and used for high-fracture-risk osteoporosis.
Status
FDA Approved
Typical dose
80mcg
Researched for
Osteoporosis, bone health, fracture risk reduction
Trial progress
- PrePreclinical
- IPhase I
- IIPhase II
- IIIPhase III
- IVPhase IV
- FDAFDA approved
FDA approved - FDA-approved for specific uses with established human evidence
Use the tools
Stay current
Get updates on Abaloparatide
New studies, regulatory decisions and data corrections - delivered when they land.
In plain language
- Synthetic 34-amino-acid PTHrP analog also known as Tymlos or BA058.
- FDA approved for high-fracture-risk osteoporosis in postmenopausal women and men.
- Source-reported dosing is 80 mcg once daily by injection.
- Researched for osteoporosis, bone health, and fracture risk reduction.
How it's thought to work
Abaloparatide is described as a PTHrP analog that engages the PTH type 1 receptor. Compared with teriparatide, the source reports a different receptor-binding profile, including preference for an RG-bound receptor state and a more transient signal. The proposed rationale is an anabolic bone effect through osteoblast-driven formation with less stimulation of resorption and calcium elevation than might occur with longer PTHR1 signaling.
What the research shows
Where the research stands
The source highlights randomized clinical evidence from the ACTIVE phase 3 trial in more than 2,400 postmenopausal women, comparing abaloparatide with placebo and open-label teriparatide over 18 months. It reports substantial reductions versus placebo in new vertebral and nonvertebral fractures and a favorable comparison with teriparatide for major osteoporotic fractures in that dataset. It also notes cardiovascular safety analyses, transient heart-rate increases as an on-label class effect, and ATOM trial bone-density data that supported the later male osteoporosis indication.
What it shows
✓ Human clinical evidence
FDA-approved for specific uses with established human evidence
△ Limitations
Use only according to approved labeling and qualified medical guidance.
Bottom line: FDA approved for osteoporosis in postmenopausal women and in men at high fracture risk; the male indication was added in December 2022. FDA Approved
Typical dosing
CommunityCommunity dataset80 mcg
daily
Community-reported entry describes abaloparatide as a PTHrP analog for osteoporosis with a binding profile that differs from teriparatide. This row is retained as reported evidence, not as medical advice. · Subcutaneous injection daily
Research dosing
Indication-specificApproved for specific uses - study doses are indication-specific
Timing & administration
Best time to take
Morning or as directed
Follow recommended protocol
Food recommendation
With or without food
Why this timing?
The source does not identify a required clock time. It indicates that regularity matters more than choosing a specific time of day, while also listing morning as a common timing option.
Possible side effects
Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.
- Hypercalciuria
- Dizziness
- Nausea
- Palpitations
- Injection site reactions
- Orthostatic hypotension
- Osteosarcoma risk in rats
Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.
Sources
- PMC - Abaloparatide reference supplied by source
- NCBI Bookshelf - Abaloparatide reference supplied by source
- Healio - FDA approval for abaloparatide in men with osteoporosis at high fracture risk
- Radius Health - Tymlos approval announcement for increasing bone density in men with osteoporosis at high fracture risk
Frequently asked questions
Sequence
AVSEHQLLHDKGKSIQDLRRRELLEKLLXKLHTA; X=Aib
One open dataset
Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.
Browse the datasetEducational resource, not medical advice. Talk to your clinician before acting on anything here.
Community discussion
Comments are moderated before they appear. Keep it evidence-focused.